Hope in Focus is delighted with the announcement that the Nobel Prize in Physiology or Medicine 2026 has been awarded to three researchers for their discoveries in optogenetics, a promising, innovative approach to restoring vision for people with advanced vision loss from inherited retinal diseases (IRDs) including Leber congenital amaurosis (LCA). We congratulate recipients Karl Deisseroth, MD, PhD, Stanford and Howard Hughes Medical Institute, Peter Hegemann, PhD, Humboldt University of Berlin, Germany, and Georg Nagel, PhD, University of Würzburg, Germany, for their groundbreaking research.
In simple terms, optogenetics bestows light sensitivity to cells that normally don’t sense light. In the retina, photoreceptors (rods and cones) are the light-sensing cells that give us vision. However, when someone’s photoreceptors degenerate because of a retinal disease, they lose vision. Using the concepts they learned from the Nobel recipients and other innovators, retinal researchers discovered ways to enable bipolar and ganglion cells in the retina to sense light and restore some vision. These cells don’t naturally sense light, but they often survive after photoreceptors are lost. So, when treated with optogenetic therapies, bipolar and ganglion cells can work like a backup system for photoreceptors.
Excitingly, optogenetics is in clinical trials for IRDs and is showing encouraging results. Several approaches are restoring rudimentary vision to people with advanced vision loss from retinitis pigmentosa (RP) and Stargardt disease. The biotech Nanoscope is seeking approval from the US Food and Drug Administration (FDA) for its optogenetics approach for RP and expects a decision in the first half of 2027. While optogenetics is not in clinical trials yet for people with LCA, it holds potential for restoring some vision to LCA patients. Importantly, the approach works independently of the patient’s mutated gene causing vision loss.
Other companies in clinical trials for optogenetic approaches for IRDs include: Ray Therapeutics, Bionic Sight, and Restore Vision.
Optogenetics has applications beyond retinal conditions. It is being used to study and control nerve cells in the brain to better understand how these cells work and develop new treatments for myriad neurological conditions.
The discovery of optogenetics was inspired by Dr. Deisseroth’s research into algae. He wondered how algae knew to swim toward light, its essential energy source. The answer was a protein called channelrhodopsin. Fast forward a few years and researchers began developing optogenetic therapies for IRDs that express channelrhodopsin and other light-sensing proteins.
Who knew the power of pond scum?
This article was written without AI. The author used some AI for researching the news and concepts.